{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:53:20Z","timestamp":1776779600698,"version":"3.51.2"},"reference-count":75,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clml.2024.06.009","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T16:57:31Z","timestamp":1719939451000},"page":"770-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of Autologous Stem Cell Transplantation in Systemic Light Chain Amyloidosis"],"prefix":"10.1016","volume":"24","author":[{"given":"Harsh","family":"Parmar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-3870","authenticated-orcid":false,"given":"David","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.06.009_bib0001","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"25","key":"10.1016\/j.clml.2024.06.009_bib0002","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2024.06.009_bib0003","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Results of the phase 3 VITAL study of NEOD001 (Birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for mayo stage iv patients","volume":"142","author":"Gertz","year":"2019","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.clml.2024.06.009_bib0004","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.06.009_bib0005","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.11413","article-title":"Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response","volume":"92","author":"Gertz","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2024.06.009_bib0006","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"15","key":"10.1016\/j.clml.2024.06.009_bib0007","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.06.009_bib0008","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443200","article-title":"Immunoglobulin light-chain amyloidosis: From basics to new developments in diagnosis, prognosis and therapy","volume":"135","author":"Muchtar","year":"2016","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.clml.2024.06.009_bib0009","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12014-016-9133-x","article-title":"Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry","volume":"13","author":"Mollee","year":"2016","journal-title":"Clin Proteomics"},{"issue":"24","key":"10.1016\/j.clml.2024.06.009_bib0010","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2024.06.009_bib0011","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1182\/blood.V122.21.3143.3143","article-title":"Risk of progression of localised amyloidosis to systemic disease in 606 patients over 30 years","volume":"22","author":"Mahmood","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.06.009_bib0012","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ajh.25915","article-title":"Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression","volume":"95","author":"Basset","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2024.06.009_bib0013","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.clml.2024.06.009_bib0014","first-page":"1158","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"95","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.06.009_bib0015","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.06.009_bib0016","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.clml.2024.06.009_bib0017","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.06.009_bib0018","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41409-020-0990-6","article-title":"Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation","volume":"56","author":"Al Saleh","year":"2021","journal-title":"Bone Marrow Transplantation"},{"issue":"8","key":"10.1016\/j.clml.2024.06.009_bib0019","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1253\/circrep.CR-19-0063","article-title":"Renal clearance of N-terminal pro-brain natriuretic peptide is markedly decreased in chronic kidney disease","volume":"1","author":"Tsutamoto","year":"2019","journal-title":"Circ Rep"},{"issue":"1","key":"10.1016\/j.clml.2024.06.009_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/01.CIR.0000109483.45211.8F","article-title":"Impaired renal clearance explains elevated troponin t fragments in hemodialysis patients","volume":"109","author":"Diris","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.clml.2024.06.009_bib0021","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1704346","article-title":"High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial","volume":"33","author":"Sanchorawala","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2024.06.009_bib0022","first-page":"1133","article-title":"Impact of bone marrow plasmacytosis on outcome in patients with al amyloidosis following autologous stem cell transplant","volume":"34","author":"Hwa","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.06.009_bib0023","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ajh.24453","article-title":"Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation","volume":"91","author":"Hwa","year":"2016","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2024.06.009_bib0024","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2016.05.027","article-title":"The effect of bone marrow plasma cell burden on survival in patients with light chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation","volume":"22","author":"Dittus","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.clml.2024.06.009_bib0025","first-page":"1083","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","year":"2008","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2024.06.009_bib0026","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/cncr.30051","article-title":"Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis","volume":"122","author":"Gertz","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2024.06.009_bib0027","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3324\/haematol.2014.119198","article-title":"Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase ii HOVON-41 study by the dutch-belgian co-operative tria","volume":"100","author":"Hazenberg","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2024.06.009_bib0028","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.06.009_bib0029","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1097\/HS9.0000000000000681","article-title":"Summary of the EHA-ISA working group guidelines for high-dose chemotherapy and stem cell transplantation for systemic AL amyloidosis","volume":"6","author":"Sanchorawala","year":"2022","journal-title":"HemaSphere"},{"issue":"10","key":"10.1016\/j.clml.2024.06.009_bib0030","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.11325","article-title":"Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.clml.2024.06.009_bib0031","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.06.009_bib0032","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ajh.25746","article-title":"Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis","volume":"95","author":"Sidana","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.06.009_bib0033","doi-asserted-by":"crossref","DOI":"10.1080\/13506129.2020.1802713","article-title":"Next generation flow cytometry for MRD detection in patients with AL amyloidosis","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.clml.2024.06.009_bib0034","first-page":"117","article-title":"The use of next generation gene sequencing to measure minimal residual disease in patients with al amyloidosis and low plasma cell burden: a feasibility study","volume":"134, 11","author":"Sarosiek","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.06.009_bib0035","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.bbmt.2017.11.040","article-title":"Adverse prognostic factors for morbidity and mortality during peripheral blood stem cell mobilization in patients with light chain amyloidosis","volume":"24","author":"Yeh","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.clml.2024.06.009_bib0036","first-page":"2345","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood Preprint at"},{"issue":"6","key":"10.1016\/j.clml.2024.06.009_bib0037","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/jca.21747","article-title":"An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis","volume":"34","author":"Badar","year":"2019","journal-title":"J Clin Apher"},{"issue":"3","key":"10.1016\/j.clml.2024.06.009_bib0038","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/13506129.2014.900486","article-title":"Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series","volume":"21","author":"Lee","year":"2014","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.clml.2024.06.009_bib0039","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.bbmt.2017.07.015","article-title":"Comparison of different stem cell mobilization regimens in AL amyloidosis patients","volume":"23","author":"Lisenko","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.clml.2024.06.009_bib0040","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1537-2995.2005.00597.x","article-title":"Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis","volume":"45","author":"Perotti","year":"2005","journal-title":"Transfusion (Paris)"},{"issue":"8","key":"10.1016\/j.clml.2024.06.009_bib0041","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib\/thalidomide\/dexamethasone in the phase III CASSIOPEIA study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2024.06.009_bib0042","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/ajh.25654","article-title":"Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma","volume":"95","author":"Al Saleh","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2024.06.009_bib0043","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ajh.25566","article-title":"Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2024.06.009_bib0044","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bmt.1704826","article-title":"Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis","volume":"35","author":"Oran","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2024.06.009_bib0045","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","article-title":"Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone \u00b1 thalidomide for systemic light-chain amyloidosis: results of a phase II trial","volume":"139","author":"Cohen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.06.009_bib0046","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2012.274","article-title":"Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis","author":"Landau","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2024.06.009_bib0047","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ajh.25572","article-title":"Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis","volume":"94","author":"Al Saleh","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.clml.2024.06.009_bib0048","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.3390\/jcm9113778","article-title":"Al amyloidosis: the effect of maintenance therapy on autologous stem cell transplantation outcomes","volume":"9","author":"Ozga","year":"2020","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.clml.2024.06.009_bib0049","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-018-0137-9","article-title":"Deferred autologous stem cell transplantation in systemic AL amyloidosis","volume":"8","author":"Manwani","year":"2018","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2024.06.009_bib0050","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.3324\/haematol.2014.108191","article-title":"Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting","volume":"99","author":"Venner","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2024.06.009_bib0051","first-page":"1297","article-title":"Similar survival with deferred versus salvage autologous stem cell transplant in light chain amyloidosis","volume":"55","author":"Luan","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.06.009_bib0052","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41409-020-0964-8","article-title":"Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis","volume":"55","author":"Abdallah","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2024.06.009_bib0053","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/bmt.2010.239","article-title":"A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis","volume":"46","author":"Quillen","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2024.06.009_bib0054","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jtct.2021.03.031","article-title":"Second stem cell transplantation for relapsed refractory light chain (AL) amyloidosis","volume":"27","author":"Muchtar","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.clml.2024.06.009_bib0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/bbmt.2001.v7.pm11400951","article-title":"Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies","volume":"7","author":"Somlo","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2024.06.009_bib0056","first-page":"589","article-title":"Allogeneic bone marrow transplantation for AL amyloidosis","volume":"27","author":"Guillaume","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2024.06.009_bib0057","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1046\/j.1365-2141.1998.00527.x","article-title":"Allogeneic bone marrow transplantation for systemic AL amyloidosis","volume":"100","author":"Gillmore","year":"1998","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.06.009_bib0058","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1600-0609.2004.00250.x","article-title":"Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan","volume":"72","author":"Kawai","year":"2004","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.06.009_bib0059","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ajh.20544","article-title":"Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis","volume":"81","author":"Imamura","year":"2006","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2024.06.009_bib0060","first-page":"165","article-title":"Heart transplantation for cardiac amyloidosis: Successful one-year outcome despite recurrence of the disease","volume":"7","author":"Conner","year":"1988","journal-title":"J Heart Transplant"},{"issue":"10","key":"10.1016\/j.clml.2024.06.009_bib0061","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.healun.2003.08.027","article-title":"Cardiac transplantation for amyloid heart disease: the United Kingdom experience","volume":"23","author":"Dubrey","year":"2004","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.clml.2024.06.009_bib0062","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","article-title":"Solid organ transplantation in AL amyloidosis","volume":"10","author":"Sattianayagam","year":"2010","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.clml.2024.06.009_bib0063","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1600-6143.2005.00920.x","article-title":"Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement","volume":"5","author":"Leung","year":"2005","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.clml.2024.06.009_bib0064","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","article-title":"Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation","volume":"26","author":"Herrmann","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.clml.2024.06.009_bib0065","first-page":"796","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","volume":"96","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.clml.2024.06.009_bib0066","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.clml.2024.06.009_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.clml.2024.06.009_bib0068","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/bmt.2016.132","article-title":"Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis","volume":"51","author":"Lee","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2024.06.009_bib0069","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23991","article-title":"Outcome of patients with multiple myeloma and hypotension during high-dose chemotherapy","volume":"90","author":"Biran","year":"2015","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.06.009_bib0070","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1182\/blood-2021-151573","article-title":"Droxidopa for treatment of refractory orthostatic hypotension in patients with AL Amyloidosis: a case series","volume":"138","author":"Ruiz Lopez","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.06.009_bib0071","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bmt.2012.253","article-title":"Factors affecting the development of atrial fibrillation and atrial flutter (AF\/AFL) following autologous hematopoietic SCT (auto-HSCT)","volume":"48","author":"Steuter","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2024.06.009_bib0072","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/clc.20904","article-title":"Melphalan-induced supraventricular tachycardia: incidence and risk factors","volume":"34","author":"Feliz","year":"2011","journal-title":"Clin Cardiol"},{"issue":"9","key":"10.1016\/j.clml.2024.06.009_bib0073","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/bmt.2017.148","article-title":"The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution","volume":"52","author":"Arun","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2024.06.009_bib0074","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.21459","article-title":"Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation","volume":"84","author":"Fatema","year":"2009","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.06.009_bib0075","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1046\/j.1523-1755.2003.00936.x","article-title":"Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis","volume":"63","author":"Fadia","year":"2003","journal-title":"Kidney Int"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:09:54Z","timestamp":1729595394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2152265024002428"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Autologous Stem Cell Transplantation in Systemic Light Chain Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}